STAT+: Amgen spends $1.9 billion on Five Prime, eyeing an expansion in Asia



Amgen said Thursday it will purchase Five Prime Therapeutics for $1.9 billion to obtain a potential treatment for gastric cancer, a move that will also expand the biotech giant’s focus in Asia.

The deal represents a major victory for Five Prime, which traded as low as $2.17 last March. The company’s stock jumped in November, when key results from a study of its gastric cancer drug, bemarituzumab, were released, and have continued to rise since.

Continue to STAT+ to read the full story…

Source link

Comments are closed, but trackbacks and pingbacks are open.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy